Evolution Wealth Advisors, LLC Vertex Pharmaceuticals Inc Transaction History

Evolution Wealth Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 28, 2022	SELL	$177.01 - $223.45 $21,418 - $27,037	-121 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$181.39 - $202.99 $29,203 - $32,681	-161 Reduced 57.09%	121 $22,000
Q2 2021 Jul 22, 2021	BUY	$187.49 - $221.1 $1,499 - $1,768	8 Added 2.92%	282 $57,000
Q1 2021 Apr 20, 2021	BUY	$207.02 - $241.31 $13,456 - $15,685	65 Added 31.1%	274 $59,000
Q4 2020 Feb 02, 2021	BUY	$207.01 - $276.09 $9,315 - $12,424	45 Added 27.44%	209 $49,000
Q3 2020 Oct 15, 2020	SELL	$255.65 - $303.1 $2,812 - $3,334	-11 Reduced 6.29%	164 $45,000
Q2 2020 Jul 27, 2020	BUY	$225.48 - $295.8 $4,735 - $6,211	21 Added 13.64%	175 $51,000
Q1 2020 Apr 22, 2020	SELL	$199.77 - $247.81 $11,786 - $14,620	-59 Reduced 27.7%	154 $37,000
Q4 2019 Feb 03, 2020	BUY	$166.71 - $223.91 $27,340 - $36,721	164 Added 334.69%	213 $47,000
Q3 2019 Nov 12, 2019	SELL	$166.23 - $187.09 $20,446 - $23,012	-123 Reduced 71.51%	49 $8,000
Q2 2019 Jul 12, 2019	BUY	$164.61 - $190.37 $28,312 - $32,743	172 New	172 $32,000

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Evolution Wealth Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Evolution Wealth Advisors, LLC with notifications on news.